𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide

✍ Scribed by Ioulia Chatzistamou; Andrew V. Schally; Jozsef L. Varga; Kate Groot; Patricia Armatis; Ana Bajo

Book ID
106124903
Publisher
Springer-Verlag
Year
2001
Tongue
English
Weight
154 KB
Volume
127
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Novel antagonists of growth hormone-rele
Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers
✍ Anna Klukovits; Andrew V. Schally; Luca Szalontay; Irving Vidaurre; Andrea Papad πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 877 KB

## Abstract ## BACKGROUND: Antagonists of growth hormone‐releasing hormone (GHRH) inhibit the proliferation of various human cancer cell lines and experimental tumors by mechanisms that include direct action on GHRH receptors in cancer cells. ## METHODS: In this study, the effects of newly synth

Inhibition of PC-3 human prostate cancer
Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity
✍ Artur Plonowski; Jozsef L. Varga; Andrew V. Schally; Magdalena Krupa; Kate Groot πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 202 KB

## Abstract Vasoactive intestinal peptide (VIP) stimulates the proliferation and invasiveness of malignant prostatic cells. Receptors for VIP and the closely related growth hormone‐releasing hormone (GH‐RH) show considerable homology and are found in prostatic and other carcinomas. Among various an